Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.

Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS.

J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. Epub 2007 Dec 18.

2.

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.

Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A.

CNS Drug Rev. 2006 Summer;12(2):123-34. Review.

3.

"Broad spectrum" antidepressants: is more better for the treatment of depression?

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Life Sci. 2003 Nov 7;73(25):3175-9. Review.

PMID:
14561522
4.

Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.

Bello NT, Zahner MR.

Curr Opin Investig Drugs. 2009 Oct;10(10):1105-16. Review.

PMID:
19777399
5.

Triple reuptake inhibitors ("broad spectrum" antidepressants).

Skolnick P, Basile AS.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):141-9. Review.

PMID:
17430151

Supplemental Content

Support Center